PACS Insiders Net $35.7M as Analyst Target Sits at $59
PACS Group's co-founder and CEO has made 20 consecutive open-market sales of company stock since mid-August 2026, all at prices between $42 and $45 — while the analyst consensus target sits at $59 and
PACS Insiders Net $35.7M as Analyst Target Sits at $59
NEW YORK, September 13 —
PACS Group, Inc. (PACS) offers a clean test of whose valuation to trust: a CEO who made 20 consecutive open-market sales at $42 to $45, or analysts holding a $59 consensus target. The selling ran through the company's third straight earnings beat and a 32-facility Florida acquisition, developments that should build conviction, not prompt a founder to exit.
- Q2 2026 EPS of $0.63 beat the $0.56 consensus by 12.5%, the company's third straight quarterly beat.
- CEO Murray sold in 20 straight transactions; combined insider proceeds totaled $35.7 million in 90 days, with zero purchases.
- $3.40 billion total debt, $160 million cash; 16.5x forward P/E against a $59 consensus target.
Three Beats and a Florida Footprint
PACS Group, Inc. operates skilled nursing and assisted living facilities across the United States, with an ownership layer in healthcare-related real estate alongside its clinical services. Trailing-twelve-month revenue reached $5.55 billion, up 9.1% year-over-year, on free cash flow of $378 million. Q2 2026 EPS of $0.63, reported in the August 4 8-K, beat consensus by 12.5%, the third straight beat extending a run that began with a 56.5% positive surprise in Q1. A 32-facility Florida acquisition announced September 9 lifted shares 3.3%. Three consecutive upside quarters and an accelerating acquisitions pipeline constitute the bull case; the insider trading that began the same week complicates it.
The Selling Pattern
Murray, the co-founder and CEO, made 20 open-market sales between August 17 and September 9, at prices from $42.35 to $44.85 per share; the heaviest two days, August 19 and 20, covered four transactions and more than 175,000 shares. Director and 10% beneficial owner Mark Hancock logged the window's largest single trade on July 6: 142,163 shares at $45.33, generating $6.44 million. President and COO Joshua Jergensen added five more sales in July and August. No officer or director purchased a single share in the period; net proceeds totaled $35.7 million. The preset trading plan cited in news reports makes the selling routine in form, not in character.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PACS | $7.1B | 16.5x | +329.1% |
| BTSG | $11.6B | 25.8x | +116.1% |
| SEZL | $4.0B | 17.9x | +32.0% |
| ULS | $14.4B | 27.4x | +5.5% |
| LOAR | $6.2B | 41.1x | -14.4% |
| CGON | $6.4B | n/a | +109.1% |
What the Target Requires
The analyst consensus of that figure against $44.76, a 32% premium, prices in real compounding from a company carrying $3.40 billion in debt and $160 million cash. That is achievable on PACS's 9.1% revenue trajectory and active acquisition pipeline, as a DCF stress-test shows, but only over a horizon that appears longer than the selling window. Insiders holding 69.1% of the float are best positioned to judge that horizon, and their revealed preference is reduction at $42-45. Q3 2026 earnings are the nearest checkpoint: a fourth consecutive beat confirms the thesis; a miss reopens the valuation debate. Run the free PACS Group, Inc. deep-dive → before that number lands.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
PACS Group's co-founder and CEO has made 20 consecutive open-market sales of company stock since mid-August 2026, all at prices between $42 and $45 — while the analyst consensus target sits at $59 and the company just announced a 32-facility Florida acquisition. The selling campaign began weeks after the company's third straight earnings beat.